Half Of Targeted Indian Hospitals Clear Cel-Sci Phase III Cancer Trial
This article was originally published in PharmAsia News
Executive SummaryHalf of participating Indian hospitals have cleared Austria's Cel-Sci to enroll patients for Phase III trials of its Multikine drug to treat head-and-neck cancer
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.